3650 Gilmore Way
Burnaby, BC V5G 4W8
Full-time employees: 149
|Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D.||Exec. Chairman||1.01M||N/A||1968|
|Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA||Pres, CEO & Director||957.16k||N/A||1976|
|Ms. Sherry Aulin||Chief Financial Officer||458.64k||N/A||1984|
|Dr. Christopher John Kenney M.D.||Chief Medical Officer||494.83k||N/A||1971|
|Ms. Jodi Regts M.B.A., B.A., MBA||VP of Corp. Affairs & Investor Relations||N/A||N/A||N/A|
|Ms. Shelley McCloskey B.A.||Sr. VP of HR||N/A||N/A||1960|
|Dr. Robin P. Sherrington Ph.D.||Exec. VP of Strategy & Innovation||N/A||N/A||1961|
|Dr. James R. Empfield Ph.D.||Exec. VP of Drug Discovery||N/A||N/A||1961|
|Ms. Sheila M. Grant M.B.A., M.Sc., MBA||Sr. VP of R&D Operations||N/A||N/A||N/A|
|Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.||Chief Commercial Officer||N/A||N/A||1979|
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.